ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/24/201508:11:01Is This The Biggest Threat to Isis Pharmaceuticals Stock?
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:52:39How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures...
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/18/201519:18:18How The Rushed Biosimilar Law Is Yielding Go-Slow Launches
03/18/201507:45:27AstraZeneca combo lung disease drug successful in Phase 3 studies
03/17/201517:24:32ADR Shares End Mixed; BHP Billiton Shares Rise
03/17/201507:35:19New indication for Novartis bone marrow disorder drug cleared...
03/17/201504:45:54Novartis Gets EU Approval for Jakavi Rare Blood Cancer Drug
03/13/201515:51:14Oxford Biomedica Hails Novartis Contract, Narrows Loss
03/13/201506:30:41Wall Street Breakfast: Japan Marches Higher As Nikkei Breaches...
03/12/201516:33:14GSK Plans Partial Stake Sale in Aspen Pharmacare
03/12/201516:32:28GSK Plans to Sell About Half Its 12.4% Stake in Aspen Pharmacare...
03/10/201521:51:04Cellectis: Finding Value In A Crowded CAR-T Space
03/10/201507:48:59Ophthotech earns $50M Fovista milestone from Novartis
03/05/201508:06:10Arrowhead buys Novartis' RNAi assets

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad